MedTrace Logo

Dose-Exposure-Response in Type 1 Diabetes Mellitus

NCT00368394 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 18

Last updated 2006-08-24

No results posted yet for this study

Summary

To investigate the dose-exposure-response relationship of insulin glulisine (HMR1964) after single subcutaneous injections of 0.075, 0.15 and 0.3 U/kg body weight with the euglycaemic clamp technique using the Biostator (TM).

Conditions

  • Diabetes Mellitus, Type I

Interventions

DRUG

Insulin glulisine

Sponsors & Collaborators

Principal Investigators

  • Klaus Rave Dr, med · Profil Institut für Stoffwechselforschung GmbH, Neuss, Germany

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-01-31

Countries

  • Germany

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00368394 on ClinicalTrials.gov